Hikma Pharmaceuticals PLC
Closed
SectorHealthcare
1,551 1.57
Overview
Share price change
24h
Min
1526
Max
1532
Income | 56M 221M |
|---|---|
Sales | 15M 1.7B |
P/E Sector Avg | 12.477 56.597 |
Dividend yield | 5.38 |
Profit margin | 12.905 |
Employees | 9,500 |
EBITDA | 67M 478M |
Dividend yield Sector Avg | 5.38% 2.18% |
|---|---|
Next Dividend date | 17 wrz 2026 |
Market Cap | 70M 3.4B |
|---|---|
Previous open | 1549.43 |
Previous close | 1551 |
News Sentiment
By Acuity
50%
50%
124 / 339 Ranking in Healthcare
Hikma Pharmaceuticals PLC Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Hikma Pharmaceuticals PLC Forecast
Sentiment
By Acuity
124 / 339 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.